Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD9592 |
Synonyms | |
Therapy Description |
AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD9592 | AZD 9592|AZD-9592 | EGFR Antibody 60 MET Antibody 31 | AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05647122 | Phase I | AZD9592 AZD9592 + Osimertinib | First in Human Study of AZD9592 in Solid Tumors (EGRET) | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 5 |